ArticleAnnals of thoracic surgery short reports2024
Long-Term Survival After Pneumonectomy for Major Hemoptysis in Advanced Non-Small Cell Lung Cancer.
Article in Annals of thoracic surgery short reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Narrative review of the progress in the treatment of hemoptysis among patients with advanced lung cancer.Journal of thoracic disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 65-year-old man was admitted for a tissue biopsy of suspected right middle and lower lobe lung cancer with multiple bone metastases. During hospitalization, he started to cough up blood, which recurred after intubation. The patient experienced asphyxia, which led to cardiopulmonary arrest, but was successfully resuscitated. For complete hemostasis, palliative right pneumonectomy was performed. The decision to perform a pneumonectomy at an early stage contributed to saving the patient's life. By the time of reporting, he had survived for almost 6 years on tyrosine kinase inhibitors administered to control the primary disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.